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ABSTRACT 
Background and Objectives: We studied a large series of ductal carcinoma in situ with 
microinvasion (MIDC) an infrequent disease whose diagnosis and management are not well defined.  
Methods: 17,431 cases of breast carcinoma were treated between 2011 and 2016 by ten Italian Breast 
Units. Our analysis included diagnostic and clinic-pathological characteristics, surgical management, 
and the use of adjuvant therapies. 
Results: 15,091 cases (86.6%) were infiltrating carcinomas (IC), 2,107 (12.1%) ductal carcinoma in 
situ (DCIS), and 233 (1.3%) MIDC. Age at diagnosis did not differ between DCIS and MIDC. MIDC 
were usually larger and expressed more frequently biologically aggressive features (higher Ki67 
values, hormone receptor negativity and HER2/neu over-expression) (p<0.01). Axillary lymph nodes 
were involved in 25 MIDC cases (12%), but >3 lymph nodes were involved in two cases only (1%). 
At multivariable analysis, only lymphovascular invasion (LVI) was associated with lymph node 
status (p<0.01). Hormone therapy was prescribed in 388/1,462 DCIS cases (26.5%), in 84/200 MIDC 
cases (42%), and in 11,086/14,188 IC cases (84.7%) (p<0.01). Chemotherapy was administered in 
28/190 MIDC cases (14.7%), and in 4,080/11,548 IC cases (35.3%) (p<0.001).  
Conclusions: This is one of the largest studies of MIDC reported in the literature. Approximately 
10% of DCIS harbor one or more foci of MIDC, and the latter often expresses aggressive biological 
features. LVI is a predictor of axillary node involvement, but this is infrequent and usually limited. 
Conservative surgery is performed less often than in DCIS, and adjuvant chemotherapy is less 
frequently utilized compared to IC.  
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INTRODUCTION 
Over the past two decades, the widespread use of mammographic screening for breast carcinoma has 
dramatically increased the diagnosis of ductal carcinoma in situ (DCIS) 1. In the United States, 
DCIS incidence rose from 1.87 per 100,000 in 1973-1975 to 32.5 per 100,000 in 2004,  particularly 
in women older than 50 years. While in the past DCIS accounted for fewer than 5% of breast cancers,  
it currently represents 20%–30% of cases, and 30%–50% of all mammographically detected cancers. 
2.  
Similarly, improvements of mammographic screening programs have contributed to a more frequent 
diagnosis of small invasive breast cancers in recent years. A particular subset of such malignancies 
is represented by microinvasive ductal carcinoma (MIDC), defined as a stromal invasion smaller than 
1 mm in diameter 3. MIDC accounts for about 1% of all breast cancer cases, and while the vast 
majority of MIDC are found within DCIS lesions, the former is associated with DCIS in 
approximately 5–10% of cases 4. 
The fifth edition of the AJCC Cancer Staging Manual published in 1997 was the first to recognize a 
specific T substage for MIDC, formally reported as pT1mic 5.  
It is well recognized that DCIS is not a single disease, as it shows several different biological 
behaviors based on histological features, hormone receptor status, growth factor receptor status, 
proliferation rate, and probably genetic signature 6. The biology of MIDC is also not well 
understood, and both the significance of microinvasion and its clinical management are controversial. 
Usually, pathologic features of MIDC show adverse prognostic factors compared to DCIS 7,8,9, 
and the former is typically associated with larger DCIS tumors, whose histology exhibits high-grade 
features and  comedo patterns 10. However,  its true metastatic potential is still unclear 11.  
Due to the rare diagnosis of MIDC,  its infrequent inclusion in large published cohorts of patients and 
its unclear clinical behavior, very little evidence is available to guide management of this disease. 
Thus far, few large, multicentric experiences with MIDC have been published in the literature 4. 
The aim of this study is to describe a large, multicentric, series of MIDC with a focus on diagnosis, 
pathological features and treatment, to compare MIDC with DCIS and IC, and to study the 
relationship of MIDC characteristics with lymph node involvement. 
MATERIALS  AND METHODS 
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Approval by the Institutional Review Boards of the participating Institutions was waived because 
data was de-identified and analyzed in aggregate. 
Data were obtained from ten prospectively maintained databases of Breast Centers associated with 
Senonetwork Italia (www.senonetwork.it), a non for profit organization aiming at building a network 
of Italian Breast Centers and promote quality of care. All patients were treated between 2011 and 
2016.  For data recording all Centers used DataBreast (www.databreast.com), implemented for the 
control of the quality indicators [12] recommended by Eusoma (European Society of Breast Cancer 
Specialists).  
The following information were available: age at diagnosis, mammographic BIRADS score, presence 
or absence of microcalcifications and mammographic pattern (architectural pattern, irregular opacity 
of the breast tissue , mass diameter, architectural distortion and focal asymmetry), ultrasound features, 
clinical features, results and diagnostic testing including fine needle aspiration cytology (FNAC) and 
needle biopsy, histologic type of DCIS, presence or absence of necrosis, in situ component of invasive 
carcinoma, Grade of in situ ad invasive cancer, lymph node status, estrogen receptor (ER), 
progesteron receptor (PgR),  HER2/neu status, Ki-67 value, surgical treatment of the breast and axilla, 
type of adjuvant treatment including chemotherapy, radiotherapy and hormonal therapy.  The dataset 
did not specify for the type of needle biopsy (either core or vacuum-assisted biopsy),  nor for the 
gauge of the needle used to obtain the samples. 
Diagnostic features at ultrasound and mammography were classified according to the method 
proposed by the American College of Radiology [13], and FNAC and FNAB results were classified 
according to the European Guideline of Quality Assurance in Breast Cancer Screening and Diagnosis 
(European Commission 2006) [14] .  
Generally, immunohistochemistry studies were performed on surgical specimens, and in case of 
MIDC the most representative portion was chosen. 
We primarily analyzed the entire cohort of MIDC cases, describing baseline characteristics, 
pathologic features, and cancer subtype distribution, in order to find any specific identifying profile 
of this rare tumor. Than we compared this group with DCIS and IC cases.  
Finally, two of the Authors (LC and MTL) searched on Medline/PubMed (www.ncbi.nlm.nih.gov) 
the literature on MIBC (search for “microinvasive breast carcinoma” or “microinvasive breast 
cancer”), with no restrictions on the date of publication. The relevant papers were selected by reading 
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the abstracts and the full text. The references of the selected papers were then used to identify 
additional relevant studies. 
Statistical Analysis 
Statistical analysis was performed with the statistical package R. Student’s t-test for significance 
between means and binomial analyses using Pearson’s χ2 test were performed. Characteristics of 
cases in  relation to lymph nodes status were studied by multivariable analysis. All analyses have 
excluded missing values, which are documented separately. 
The study was conducted according to the principles laid down in the declaration of Helsinki. Cases 
were de-identified and data was analyzed in aggregate. 
RESULTS 
We analyzed 17,431 breast carcinoma of which 15,091 (86.6%) were classified as IC, 2,107 (12.1%) 
as DCIS, and 233 (1.3%) as MIDC.  
Mean age at diagnosis of DCIS (57,8±12.2 years)  and MIDC (56.4±13 years) did not differ, while it 
was higher in case of IC (60.6±13,7 years) (p<0.001). Age less than 50 years was observed in 82/233 
MIDC cases (35.2%), and in 3,813/15,091 IC cases  (25.4%, p<0.05). There were no further 
statistically significant differences between age groups. 
Diagnostic features of the three groups are described in Table 1. 
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Table 1 – Diagnostic features 
 DCIS  
(n=1,705) 
MIDC  
(n=202) 
IC  
(n=12,153) 
p 
MIDC vs. IC 
p 
MIDC vs. DCIS 
R1 95  (5.6%) 15  (7.4%) 927 (7.6%)   
R2 32 (1.9%) 6 (3%) 173 (1.4%)   
R3 332 (19.5%) 19 (9.4%) 1,038 (8.5%)   
R4 1,076 (63.1%) 134 (66.3%) 7,161 (58.9%)   
R5 170 (10%) 28 (13.9%) 2,854 (23.5%)   
R4+R5 1,246 (73.1%) 162 (80.2%) 10,015 (82.4%) n.s. <0.001 
 DCIS 
(n=1480) 
MIDC  
(n=187) 
IC  
(n=14,696) 
  
US1 405 (27.4%) 26 (13.9%) 745 (2.4%)   
US2 125 (8.4%) 4 (2.1%) 273 (1.1%)   
US3 196 (13.2%) 15 (8%) 1,058 (6.5%)   
US4 619 (41.8%) 109 (58.3%) 8,297 (58.1%)   
US5 135 (9.1%) 33 (17.6%) 4,323 (31.9%)   
US4+US5 754 (50.9%) 142 (75.9%) 12,620 (90%) <0.001 n.s. 
FNAC DCIS 
 (n=355) 
MIDC  
(n=44) 
IC  
(n=5557) 
  
C1 33 (9.3%) 2 (4.5%) 302 (5.4%)   
C2 22 (6.2%) 0 70 (1.3%)   
C3 60 (16.9%) 3 (6.8%) 256 (4.6%)   
C4 80 (22.5%) 4 (9.1%) 916 (16.5%)   
C5 160 (45.1%) 35 (79.5%) 4,013 (72.2%)   
C4+C5 240 (67.6%) 39 (88.6%) 4,929 (88.7%) <0.001 n.s. 
Needle Biopsy DCIS  
(n=1675) 
MIDC  
(n=195) 
IC  
(n=10,353) 
  
B1 22 (1.8%) 3 (1.5%) 93 (0.9%)   
B2 48 (2.8%) 2 (1%) 93 (0.9%)   
B3 146 (8.7%) 3 (1.5%) 113 (1.1%)   
B4 51 (3%) 4 (2.1%) 144 (1.4%)   
B5 1,418 (84.2%) 183 (93,8%) 9,910 (95.7%)   
B4+B5 1,469 (87.2%) 187 (95.9%) 10,054 (97.1%) n.s. <0.001 
 
We found that 45/187 MIDC cases (24%) were not diagnosed by US or showed a low index of 
suspicion (US1-2-3) while this occurred in 726/1,480 DCIS cases (49%) and in 2,076/14,696 IC cases 
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(14%) (p<0.01). Similarly, mammographic findings highly suggestive of malignancy were less 
frequent in DCIS than in the other two  groups (p <0.001).  
Twenty-seven percent of DCIS, 19.8% of MIDC and 17.5% of IC showed mammographic features 
interpreted as benign (R1-2) or probably benign (R3).  Microcalcifications were detected in 
1,264/1,561 (81%) of DCIS cases, in 141/183 MIDC cases (77.9%), and only in 2,851/10,251 IC 
cases (27.8%) (p<0.01). 
Core biopsy was considerably more sensitive than FNAC (respectively 13.3% vs. 32,4% of DCIS, 
4% vs. 11.3% of MIDC and 2.9% vs. 11.3% of IC were diagnosed as inadequate, benign or probably 
benign) (p<0.001).  
The mean tumor diameter of MIDC (28,2 ± 17 mm) (including the in situ and infiltrating components) 
was significantly higher compared to that of DCIS (19,4 ± 12 mm) and IC (22±16 mm) (p<0.05).  
There was no statistically significant difference in the pattern of growth of the intraductal component 
of DCIS and MIDC groups.  
The presence of necrosis was more frequent in the MIDC group  (61/119 ; 51.3%), than in DCIS  
(301/914 ; 32.9%) or in IC group (802/3758  ; 21.3% ) (p<0.01).  
High tumor grade of the infiltrating component was more frequently in MIDC (49%) than in IC 
(28.4%) (p<0.001). 
Lymphovascular invasion (LVI) was found in 10/203 (4.9%) cases of MIDC. 
Table 2 shows the results of immunohistochemistry results, comparing expression of ER, PgR, 
HER2/neu and Ki67. 
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Table 2 - Immunohistochemistry 
 DCIS 
 
MIDC IC p 
MIDC vs IC 
p 
MIDC vs DCIS 
ER+ 920/1,142 
(80.6%) 
131/204 
(64.2%) 
12,938/14,651 
(88.3%) 
<0.001 <0.001 
PgR+ 799/1,130 
(70.7%) 
102/203 
(50.2%) 
11,361/14,612 
(77.8%) 
<0.001 <0.001 
HER2/neu+  49/129  
(38%) 
943/9,112  
(10.3%) 
<0.001  
HER2/neu 
equivocal 
 9/129  
(7%) 
1,269/9,112   
(13.9%) 
  
Ki67> 15% 103/243 
(42.4%) 
80/149 
 (53.7%) 
5,262/10,270 
 (51.2%) 
n.s. <0.005 
 
In the MIDC group Sentinel Lymph Node (SLN) biopsy was performed in 90.6% (184/203) of cases, 
SLN biopsy associated with axillary dissection in 6,4% (13/203) and an axillary dissection alone was 
chosen in  3% (6/203) of cases.   
Nodal status of the three groups are described in Table 3.  
Table 3 – Lymph node status 
 DCIS 
(n=2,107) 
MIDC 
(n=203) 
IC 
(n=13,984) 
p 
MIDC vs IC 
p 
MIDC vs DCIS 
Micrometastasis 0 5 (2.4%) 420 (3%)   
1-3 lymph nodes 
macrometastasis 
0 18 (8.8%) 3,125 (22.3%)   
≥ 4 lymph nodes 
macrometastasis 
0 2 (1%) 1,587 (11.3%)   
Total lymph node 
involvement 
0 25 (12.2%) 5,132 (36.6%) <0.001 <0.001 
 
Among microinvasive cancers, only LVI was associated with lymph node status,  both at univariable 
and multivariable analysis (Table 4). 
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Table 4 – Multivariable analysis of characteristics potentially associated with lymph node status 
in MIDC 
  Total % N+ Univariable Multivariable 
  203 12.3% OR p-value OR p-value 
Grade invasive 
1-2 84 11.9% ref.  ref.  
3 86 11.6% 0.97 0.96 0.92 0.90 
G DCIS 
1-2 65 12.3% ref.  ref.  
3 109 13.8% 1.14 0.78 1.37 0.63 
ER 
Negative 67 9.0% ref.  ref.  
Positive 114 15.8% 1.91 0.20 1.93 0.36 
PgR 
Negative 94 10.6% ref.  ref.  
Positive 87 16.1% 1.61 0.28 1.61 0.47 
Ki67 
≤ 15% 61 9.8% ref.  ref.  
> 15% 74 13.5% 1.43 0.51 1,.85 0.33 
HER2/neu 
0/1+ 66 10.6% ref.  ref.  
2+/3+ 54 13.0% 1.26 0.69 1.27 0.71 
LVI 
No 149 10.1% ref.  ref.  
Yes 9 55.6% 11.17 <0,01 24.04 <0.01 
Size 
≤ 50 mm 101 11.9% ref.  ref.  
>50 mm 15 13.3% 1.14 0.87 0.46 0.471 
 
Table 5 reports the data on surgical management and post-operative therapies. 
Table 5– Surgical management and post-operative therapies 
 DCIS MIDC IC p 
MIDC vs IC 
p 
MIDC vs DCIS 
Breast conservative 
surgery (BCS) 
1,526/2057 
 (74.2%) 
132/232 
 (56.9%) 
10,258/14,906 
(68.8%) 
<0.01 <0.01 
Radiotherapy post-
BCS 
959/1,272 
 (75.4%) 
101/121 
 (83.5%) 
8,160/9,028 
 (90.4%) 
<0.05 <0.05 
Hormonal therapy 388/1462 
 (26.5%) 
84/200 
 (42%) 
10,614/12,526 
(84.7%) 
<0.01 <0.01 
Chemotherapy  28/190 
 (14.7%) 
4,080/11,548 
 (35.3%) 
<0.01  
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Treatment with hormone therapy was performed in 388 DCIS cases (26.5%), 84 MIDC cases (42%)  
and in 10,614 IC cases (84.7%) (p<0.01). The difference is largely explained by the different 
expression of ER (64.2% of the MIDC and 88.3% of the IC were positive for ER). 
 
DISCUSSION 
This observational retrospective study of prospectively collected data was based on a multicenter 
series from ten Italian Breast Centers. It is one the largest study on MIDC to date.  
In our experience MIDC represents roughly 1% of all breast carcinomas, a finding consistent with a 
large sample of 8,863 patients from the SEER database 4.  
The mean age of patients with MIDC was similar to those with DCIS, while it was significantly higher 
in women with IC. This, apart from the larger sample size, may be explained by earlier diagnosis of 
DCIS and MIDC compared to IC, and the difference (3-4 years) has been hypothesized as the possible 
latency period for the development of an invasive carcinoma 4.  
While both mammography and US proved to be for diagnosis in all the three groups, MIDC was 
statistically more often diagnosed with mammography compared to DCIS, and less often than IC by 
US. 
Radiological features were quite different in DCIS and MIDC compared to IC. In the former group, 
microcalcifications represent the major diagnostic pattern (80% of cases), while in the latter an 
irregular opacity and architectural distortion were most frequently recorded.  
Our experience confirms that MIDC generally shows more serious biological features compared with 
IC, as it is more frequently ER/PgR negative and HER2/neu positive.  
Yang et al. 10 reported high nuclear grade and predominant comedo subtype of DCIS components 
in 57.1% and 46.4% in their experience, while 86% of their patients showed DCIS with necrosis. 
Lack of expression of ER is more frequent in MIDC than in DCIS or IC, and in accordance to our 
findings this is reported in 22-33% of cases in other studies 4,7. 
Also similar to our findings, other groups reported a rate of HER2/neu overexpression in MIDC in 
about one third of cases 4,7,8, while others registered an incidence as high as 49% 15, and in their 
experience this was not associated with higher recurrence rate. Both high grade and HER2/neu+ 
MIDC or DCIS cases were more likely to be detected at breast cancer screening using mammography, 
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probably because frequently show comedonecrosis, eventually associated with pleomorphic 
microcalcifications. In our series, necrosis was present in over 50% of MIDC.  
 
It is not clear if these differences can be explained with an intrinsic biological aggressiveness of 
MIDC or with the fact that low-grade MIDC and DCIS are possibly underdiagnosed, because 
conventional methods of imaging is less sensitive in these cases.  
Studies have shown that only a fraction of women with DCIS alone later progress to invasive cancer  
16. It is possible that small, low-grade lesions escape any clinical investigation, including 
mammography. Sensitivity of mammography screening for detection of DCIS and MIDC is high; this 
fact has the potential effect of causing overestimation of the ability of mammography to detect in situ 
disease, so that hypothetical sensitivity for detecting DCIS would be biased upward 2. 
FNAB is highly preferred for diagnosis of MIDC and DCIS, and in our experience it shows a false 
negative rate of about one third compared to that of FNAC (6% vs. 20%). 
In this study, lymph node involvement was 12% in MIDC cases, approximately one third of what we 
found in IC cases.  Although the reported incidence of lymph node metastasis in the literature ranges 
from 0% to 20% 17,  in most reports it is lower than 10% 11, and it is 7.6% in the SEER series on 
8,863 patients 4. A report from the European Institute of Oncology demonstrated that while 
metastases in the sentinel lymph node were detected in 4 of 41 patients (9.7%), two of these had only 
micrometastasis and after axillary node dissections this was the only positive node in three patients 
18. Zavagno et al. 19 found four positive patients out of 43 cases (9.3%), one of which was a 
micrometastasis.  In a large serie of Matsen et al. 9 micrometastases were found in 6.3% and 
macrometastasis in 1.4% of cases, and no difference in SLN involvement was reported according to 
the number of microinvasive foci. In one study 20, patients with MIDC were divided into two 
groups according to the type of microinvasion (infiltration of the stroma by single cells, type 1 -  or 
clusters, type 2), and the incidence of axillary lymph node metastasis was 0% and 10,1%,  
respectively. 
We confirm that multiple involvement of the axillary lymph nodes (> 4 lymph nodes) is a rare event 
in MIDC (1%), and therefore SLN biopsy alone might well be an appropriate treatment in this setting 
if patients present with clinically negative axillary lymph nodes 11. Similar to what described in 
other series 9,38, using multivariable analysis, our experience shows that LVI was the only 
statistically significant variable associated with the lymph node status. 
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In addition, similar to other reports 9,15, surgical treatment was quite different in MIDC in our 
study, as breast conservative surgery was performed in only 57% of cases of such cases compared to 
69% of IC. This can be explained by the larger average size of MIDC, possibly due to extensive in 
situ component or multicentric disease.  
Hormone therapy was used to a much lesser extent in MIDC than in IC (42% vs 84%), but this partly 
reflects the different positivity for ER in the two groups (64% vs 82%). According to the NCCN 
Guidelines 23, tamoxifen or aromatase inhibitors may be considered as a strategy to reduce the risk 
of ipsilateral breast cancer recurrence in women with ER-positive DCIS and MIDC treated with 
breast-conserving therapy. 
Adjuvant chemotherapy was prescribed in our experience in 14.7% of patients with MIDC, but this 
can range in the literature from 4 to 15%  9,15.  
 
Wang et al. 16 analyzed prognosis of MIDC and DCIS, and in a multivariable analysis found that 
microinvasion was an independent prognostic factor for OS (HR, 1.2; p < 0.001). The 10-year cancer-
specific mortality rate was 1.5% in DCIS and 4% in MIDC (HR, 2.8; p < 0.001), while the 20-year 
cancer-specific mortality rate was 4 % in DCIS and 10% in MIDC (HR, 2.5;  p < 0.001).  
However, one group stated HER2/neu overexpression, although  prevalent, is not significantly 
associated with recurrence 15. Furthermore, prognosis of MIDC seems to be independent of SLN 
status, as all 18/414 patients who suffered recurrence in the MSKCC study had a negative SLN status, 
for an overall 5-year recurrence-free proportion of 95.9% 9. 
 
Table 6 summarizes data from the available literature on MIDC.  
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Tab. 6 – Results of a literature search on published MIDC series 
AUTHOR Years N 
Ag
e 
Grade 
G3 
BCS 
pN1mi 
or 
pN0(i+) 
Macro 
Metastasis 
TLNI ER+ 
HER2 
(neu)+ 
ET CHT 
Wang 4 
1990-
2012 
8863  44%    7.6% 66% 36%   
Mori 8 2006-
2009 
32 55 50%  3.6% 3.6% 7.2% 30% 59%   
Matsen 
9 
1997-
2010 
414 53 39% 48% 6.3% 1.4% 7,7% 63% 39% 39% 7.6% 
Yang 10 1998-
2002 
28 49 57%  0% 0% 0% 61% 36%   
Margalit 
15 
1997-
2005 
83 54 69% 63% 10% 0 10% 61% 49% 48% 5% 
Intra 18 1996-
2002 
41 35 47% 76% 4.9% 4.9% 9.8% 37%    
Zavagno 
19 
1999-
2004 
43  42% 70% 2.3% 7% 9.3%     
De 
Mascarel 
20 
1970-
1996 
243  54%    7%     
Vieira 
21 
1993-
2006 
21 56 76%     75%    
Hai-Fei 
Niu 24 
2006-
2013 
108      8.3% 37% 33%   
Colleoni 
25 
1997-
2001 
24  50%     62% 36% 32% 4.5% 
Guth (26 
1991-
2006 
59 57   4.5% 6.8% 
11.4
% 
    
Zavotsky 
27 
1992-
1997 
14   86%   
14.3
% 
    
Lillimoe 
28 
2001-
2015 
276 57 70% 42% 1.2% 0.4% 1.6% 85% 39% 43% 4% 
Ko 29 
1989-
2008 
293 47 29% 37% 6.1% 1.4% 7.5% 43% 58%   
Prasad 
30 
1993-
1997 
21 61 89% 48% 6.7% 6.7% 
13.4
% 
47% 50%   
Silva 31 
2008-
2015 
142 57     2.9% 66%    
Katz 32 
1998-
2003 
21 55 33% 67% 4.8% 4.8% 9.6% 67%    
Klauber-
De More 
33 
1997-
1999 
38 51   6.2% 3.1% 9.4%     
Sakr 34 
1995-
2005 
36 50 62% 33% 8.3% 0% 8.3%     
Shatat 
35 
1998-
2012 
40 58 65%  11.4% 2.9% 
14.3
% 
44% 56%   
Silver 
36 
1980-
1996 
38 56   0% 0% 0%     
Kim 37 
2003-
2014 
136 
50.
2 
69.2% 
40.4
% 
1.8% 1.8% 3.7% 
45.6
% 
57% 42%  
Orzalesi 
[38] 
1992-
2014 
174  36.8% 58.6
% 
10.3% 4% 14.3
% 
59.2
% 
73%   
Current 
study 
2011-
2016 
233 
56,
4 
49% 57% 2.4% 9.8% 
12.2
% 
64% 45% 42% 14,7% 
Legend : BCS= Breast Conservation Surgery     TLNI= Total Lymph Node Involvement      LVI= Lymphovascular 
Invasion   ET= Endocrine Therapy    CHT= Chemotherapy 
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There are several weaknesses of our study. First, we acknowledge that this is a retrospective analysis, 
although data were retrieved from prospective maintained databases. Second, some data is missing 
for several of the variables. Third, there was no centralized pathology review, and therefore diagnostic 
heterogeneity among different centers may have confounded the analysis of the available data. 
Finally, we did not have data regarding survival and disease-free survival, as this information was not 
available in the databases. 
However, we believe that our report on a large experience from several dedicated Breast Centers  
contributes to a better understanding of the diagnostic issues of this disease, and provides an insight  
on the current management of MIDC. 
 
CONCLUSIONS 
MIDC is an infrequently disease, as it only represents approximately 1% of all breast cancers. It 
shows unfavorable biological features, like comedonecrosis, HER2/neu over-expression and 
negativity for hormone receptors, more frequently than IC.  
The in situ component is usually of large size, and this explains the less frequent choice to perform  
BCS compared to IC. Lymph node involvement is never massive, but occurs 12% of cases in our 
study. Biopsy  of the sole SLN may represent the only axillary treatment in most instances. 
In our contemporary experiences, adjuvant hormonal therapy and adjuvant chemotherapy were 
prescribed in 42% and in 14% of patients with MIDC, respectively. Further studies are needed to 
better clarify this disease.  
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